Phosphodiesterase type-5 inhibitor(PDE5-i) drugs were first marketed in 1998(sildenafil) for 'on-demand' treatment of male erectile dysfunction(ED) of any origin.They selectively inhibit intrapenile PDE5 isoenz yme which in turn increases intracellular cyclic guanosine monophosphate levels,thus resul...
able but the most effective treatments are the PDE5 inhibitors (11). These agents have not only improved the management of ED over the last 6 years but have also increased patient expectations for a successful outcome (12). Sildenafil was the first PDE5 inhibitor licensed for ...
Using metal ion chelators such as EDTA blocks the catalytic activity of the enzyme and also blocks the PDE5 inhibitor, sildenafil, from binding to the catalytic domain [29,66], thereby converting PDE5 to an inactive conformation. This indicates the role of divalent metal ions in the activity...
Phosphodiesterase type 5 inhibitor (PDE-5i), a class of drugs that selectively inhibit phosphodiesterase activity, can play role in improving erectile dysfunction, treating pulmonary hypertension and other diseases, hence making it widely used in clinical practice. At times, PDE-5i-analogous drugs ...
The potential effects of PDE-5 inhibitors on the environment are not still apparent. However, ED medicines will prove to have very high usage rates in the near future, mainly because they are very diffuse and popular drugs. The availability of EDs without prescription over the Internet and thei...
from left ventricular hypertrophy. This is a dangerous increasing of heart, which leads to the most grievous outcomes. In the course of the study, the experts have found out that the implementation of PDE-5 inhibitor stopped the growth of the heart. It also prevented the alteration of its ...
Clinical Cornerstone 2005;7:47-55.Rashid A: The efficacy and safety of PDE5 inhibitors . Clin Cornerstone 2005, 7: 47–56.A Rashid.The efficacy and safety of PDE5 inhibitors. Clin Cornerstone Int . 2005... A Rashid - 《Clin Cornerstone》 被引量: 52发表: 2005年 PDE5 inhibitor efficacy...
Background / Purpose: The discontinuation rate for phosphodiesterase type 5 inhibitor (PDE5-i) use among men with erectile dysfunction (ED) appears to be high. Understanding the reasons for discontinuing PDE5-i will be necessary to optimize the response to ED treatment.The main goal of this st...
After controlling for these factors, the adjusted risks in the PDE5 inhibitor group were: 12% lower for all-cause mortality (14% vs 26%; hazard ratio [HR], 0.88) 19% lower for myocardial infarction (9.4% vs 15%; HR, 0.81) 25% lower for heart failure hospitalizations (1.0% vs 2.1%...
西地那非对PDE5的高亲和力及非常低IC50的值表明其对PDE5较其他的PDEs在体外有很强的抑制作用,这提示在体内西地那非达到治疗作用的浓度可能很低,但是药物在作用部位所需的实际浓度还受到药物代谢动力学的影响,这是因为虽然低IC50的值可反映药物的作用力强,但一种药物作用的强弱与其临床上的治疗效果并不总相一致,不...